WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Wednesday, November 26, 2014

Google spoon uses algorithms to steady tremors in people with Parkinson's and other disorders

Google Has Invented A Super Spoon To Help Parkinson's Patients

Google spoon uses algorithms to steady tremors in people with Parkinson's and other disorder

Google spoon
Anupam Pathak, a senior hardware engineer at Google, shows off the 

prototype of the Liftware Spoon he developed that helps people eat without spilling. (The Associated Press)


on November 25, 2014 at 1:02 PM, updated November 25, 2014 at 1:57 PM
0

Reddit
MOUNTAIN VIEW, Calif. — 
Google is throwing its money, brain power and technology at the humble spoon.
But these spoons are a bit more than your basic utensil: Using hundreds of algorithms, they allow people with essential tremors and Parkinson's disease to eat without spilling.
The technology senses how a hand is shaking and makes instant adjustments to stay balanced. In clinical trials, the Liftware spoons reduced shaking of the spoon bowl by an average of 76 percent.
"We want to help people in their daily lives today and hopefully increase understanding of disease in the long run," Google spokesperson Katelin Jabbari said.
Other adaptive devices have been developed to help people with tremors — rocker knives, weighted utensils, pen grips. But until now, experts say, technology has not been used in this way.
"It's totally novel," said UC San Francisco Medical Center neurologist Dr. Jill Ostrem, who specializes in movement disorders like Parkinson's disease and essential tremors.
She helped advise the inventors and says the device, which has a fork attachment, has been a remarkable asset for some of her patients.
"I have some patients who couldn't eat independently, they had to be fed, and now they can eat on their own," she said. "It doesn't cure the disease — they still have tremor — but it's a very positive change."
Google got into the no-shake utensil business in September, acquiring a small, National of Institutes of Health-funded startup called Lift Labs for an undisclosed sum.
More than 10 million people worldwide, including Google co-founder Sergey Brin's mother, have essential tremors or Parkinson's disease. Brin has said he also has a mutation associated with higher rates of Parkinson's and has donated more than $50 million to research for a cure. But the Lift Labs acquisition was not related, Jabbari said.
Lift Lab founder Anupam Pathak said moving from a small, four-person startup in San Francisco to the vast Google campus in Mountain View has freed him up to be more creative as he explores how to apply the technology even more broadly.
His team works at the search giant's division called Google(x) Life Sciences, which is also developing a smart contact lens that measures glucose levels in tears for diabetics and is researching how nanoparticles in blood might help detect diseases.
Joining Google has been motivating, said Pathak, but his focus remains on people who are now able to eat independently with his device.
"If you build something with your hands and it has that sort of an impact, it's the greatest feeling ever," he said. "As an engineer who likes to build things, that's the most validating thing that can happen."
Pathak said they also hope to add sensors to the spoons to help medical researchers and providers better understand, measure and alleviate tremors.
Shirin Vala, 65, of Oakland, has had an essential tremor for about a decade. She was at her monthly Essential Tremor group at a San Ramon medical clinic earlier this year when researchers developing the device introduced the idea and asked if anyone was interested in helping them.
As it was refined, she tried it out and gave them feedback. And when they hit the market at $295 apiece, she bought one.
Without the spoon, Vala said eating was really a challenge because her hands trembled so hard food fell off the utensils before she could eat it.
"I was shaking and I had a hard time to keep the food on a spoon, especially soup or something like an olive or tomatoes or something. It is very embarrassing. It's very frustrating," she said.
The spoon definitely improved her situation. "I was surprised that I held the food in there so much better. It makes eating much easier, especially if I'm out at a restaurant," she said.

http://health.einnews.com/article/236553047/RGyf6mZIXnVGMEK6?n=2&code=ga_qGBxHZ2aVYO4P

Tuesday, November 25, 2014

Foundation Benefit Raises Millions for Parkinson’s Research

FoxFeed Blog


Posted by  Kimberly Castleberry, November 25, 2014



Take a legendary musician. Double up on Hollywood actors and household television personalities. Sprinkle in a few hilarious comedians. And you’ve got The Michael J. Fox Foundation’s annual New York City gala “A Funny Thing Happened on the Way to Cure Parkinson’s.”
The star-studded bash was held on Saturday, November 22, at the Waldorf Astoria New York, and raised over $5.4 million for Parkinson’s research. A crowd of more than 1,000 guests were brought to their feet by a rousing performance from icon Paul Simon. The cheers only grew louder when Michael J. Fox joined him on guitar for the classic “Me and Julio Down by The Schoolyard.”
Comedian Colin Quinn hosted the benefit and was joined by fellow funny guys Tom Papa and J.B. Smoove. Board members Ryan Reynolds, Willie Geist and George Stephanopoulos were in the house, along with Katie Couric, John Slattery, Talia Balsam, Rachael Ray, Julianne Moore, Bart Freundlich and many more.
Introducing Michael’s mom to the stage, Reynolds quipped, “I’ve known Phyllis Fox for practically my entire evening. And I can say with confidence, she’s every bit the loose cannon she’s made out to be in the tabloids.”
In a night filled with heartwarming moments, one of the most touching was Michael and his mom sharing a long embrace on stage. Phyllis broke her hip a couple of weeks ago but that couldn’t stop her from attending the bash and bringing out her son.
The evening’s dinner menu was inspired by recipes from “The Pollan Family Table,” a new cookbook written by Tracy Pollan, her sisters and their mother.
Thanks to the Foundation’s Board of Directors, all costs related to the event are covered so that every penny raised goes straight to MJFF’s high-impact research programs. To date, Funny Thing has raised more than $60 million to speed a cure for Parkinson’s.

Yabao, MRC Technology to develop new therapeutics in China for Parkinson's disease


PBR Staff WriterPublished 24 November 2014
China-based Yabao Pharmaceutical has entered into an exclusive license with MRC Technology, a UK-based medical research charity, to discover, develop and commercialise new products targeting a kinase target for neurodegeneration to treat Parkinson's disease.

As part of the deal, Yabao will receive exclusive rights to discover, develop and commercialise new products in China, Taiwan and Hong Kong, while MRC Technology will retain rights in all other markets.
Yabao Pharmaceutical president R&D Dr Peng Wang said: "Yabao is pleased to be collaborating with MRC Technology, a leading UK research institute focused on improving the lives of patients through medical discovery.
"This opportunity for Yabao to expand on leading research to develop innovative products is further evidence of Yabao's growing commitment to partner the best science to treat serious diseases in China."
The collaboration is aimed at bringing new treatments to patients and improve their quality of life.
MRC Technology director of Business Development Michael Dalrymple said: "Parkinson's is a debilitating and destructive disease.
"We are pleased to combine our expertise in early drug discovery and innovation with the significant resources that Yabao Pharmaceutical Co. can bring to developing ground breaking new medicines."
MRC Technology provides professional services to organisations within the academic, charity, biotechnology and pharmaceutical sectors across the world.

http://health.einnews.com/article/236251712/CG50O9WCxDo79GuP?n=2&code=ga_qGBxHZ2aVYO4P


Monday, November 24, 2014

Parkinson's Disease sufferer to travel to Bristol for groundbreaking new treatment



By wbchris  |  Posted: November 24, 2014

29309612
Kay Cotton with her dog this summer
nt.
Kay Cotton, a West Briton columnist from Camborne, will be taking part in a trial to test whether a drug called GDNF can slow the course of the disease.

The clinical trial was first tested on 18 people to determine its safety, but will now be used on half of a further 36 people, including Mrs Cotton, who is not fazed by the prospect.
“This trial has given me some hope and I feel as though I have nothing to lose.

“It would be great to feel normal again and I can’t just sit here waiting, I have to do something about it.”
Ms Cotton, 57, has suffered from Parkinson’s for 10 years and has said she has been overwhelmed by the support of her friends and family.

It is hoped that an implant that delivers GDNF into the brain can stop dopamine-producing nerve cells from dying, a major symptom with Parkinson’s Disease.
“I’m not nervous as I live on my own and am younger than many of my friends who have the disease.

“I’m probably one of the more eligible people as at this point, I’m not too affected and it’s my responsibility to do something about it.
“I started to feel as if I had no purpose but this trial has given me a real boost and is a glimmer of hope for me.”

The project was originally shut down in 2006 after controversy regarding stem cells, but the revived £2million scheme has been funded by Parkinson's UK, with support from the Cure Parkinson's Trust and in association with the North Bristol NHS Trust.
During the nine month trial, half of the people taking part will take the real drug (GDNF), while half will receive an inactive placebo.

Not even doctors will be aware of who has been injected with what, but once the nine month period is complete, all of the participants would switch to the GDNF if it proves successful.
Ms Cotton will be travelling to Bristol on December 5 to meet with medical professionals to discuss the next phase of treatment.

Sunday, November 23, 2014

Exercise reduces Parkinson's risk




[Posted: Sun 23/11/2014 by Deborah Condon www.irishhealth.com]

People who undertake even a ‘medium amount' of exercise may reduce their risk of developing Parkinson's disease, a new study suggests.
Parkinson's is a progressive neurological disease, the symptoms of which include tremors, stiffness and slow movement. An estimated six to seven thousand people in Ireland are affected and there is no cure.
Swedish researchers followed the progress of over 43,000 men and women over a 13-year period. All of the participants' activity levels were assessed during this period, ranging from how much exercise they got to how active they were in their homes and jobs, including on their commute.
None of the participants had Parkinson's disease at the outset. They were monitored from October 1997 to December 2010 and during that time, almost 300 cases of the disease were detected.
The study found that people who spent more than six hours per week on household and commuting activities had a 43% reduced risk of developing Parkinson's, compared to people who spent less than two hours doing the same activities.
In males, a medium level of total physical activity was found to reduce the risk of Parkinson's by 45% when compared with a low level of activity.
According to the researchers from the Karolinska Institutet in Stockholm, one of the strengths of this study is that it looked at ‘the entire spectrum of daily energy output, rather than purely focusing on dedicated exercising'.
"We found that a medium level of daily total physical activity is associated with a lower risk of Parkinson's disease. The protective effect of physical activity was further supported when we summarised all available evidence from published prospective cohort studies. These findings are important for both the general population and for the healthcare of patients with Parkinson's disease," they added.
Details of these findings are published in Brain: A Journal of Neurology.


http://health.einnews.com/article/236105894/huWFPOYsjLWZH2_y?n=2&code=ga_qGBxHZ2aVYO4P

Friday, November 21, 2014

Differentiating Parkinson's disease from atypical parkinsonism - simple clinical tests


Two simple tests conducted during the neurological exam can help clinicians differentiate between early-stageParkinson's disease (PD) and atypical parkinsonism. By asking patients to perform a tandem gait test and inquiring whether they are still able to ride a bicycle, clinicians can ascertain whether medio-lateral balance is impaired, a defining characteristic of atypical parkinsonism. These findings are published in the Journal of Parkinson's Disease.
This issue of the Journal of Parkinson's Disease also marks the inauguration of a new feature, "How I examine my patient," which is designed to help improve the clinical skills of physicians, allied health professionals, and other professionals involved in the care of patients with PD and other movement disorders.
The occurrence of a sideways or medio-lateral balance impairment is a "red flag" of atypical parkinsonism conditions, such as multiple system atrophy (MSA), progressive supranuclear palsy, or vascular parkinsonism. As the condition progresses, patients with this deficit often compensate by adopting a wide-based walking pattern, probably reflecting widespread pathologic brain involvement of the cerebellum and brain stem, explains Jorik Nonnekes, MD, of the Radboud University Medical Center, Department of Rehabilitation, Nijmegen, the Netherlands.
In contrast, patients with PD develop a shuffling gait, maintaining a narrow distance between their feet. Because medio-lateral balance is preserved, a PD patient may still be able to ride a bicycle even when walking is difficult.
In the first test, 36 patients with PD and 49 patients with atypical parkinsonism were given a tandem gait test. Patients were instructed to take 10 consecutive steps along an imaginary straight, thin line, toe-to-heel. An abnormal tandem gait was scored if one or more side steps were needed to maintain balance. The researchers found that 18% of patients with atypical parkinsonism were able to perform the tandem gait test without a single side step, compared with 92% of patients with PD. The results were similar for patients with only early disease (< 3 years).
Another study included 45 patients with PD and 64 patients with atypical parkinsonism, all of whom said they previously rode bicycles before the onset of motor symptoms. When asked if they still were able to ride a bicycle, 52% of the atypical parkinsonism patients said they had stopped cycling compared to 2% of those with PD.
"Both tests are easy to perform in clinical practice and have a good diagnostic accuracy, even early in the course of the disease," says Dr. Nonnekes. He adds that the tests should always be judged in the clinical context and presence of other red flags or supportive features.
In the new "How I examine my patient," feature researchers and clinicians will contribute practical information about how to conduct good neurological examinations. In many cases, the literature and even neurological textbooks do not include practical descriptions of very common clinical tests.
In the first example, "How I examine my patient: The art of neurological examination for Parkinson's disease and atypical parkinsonism," authors Bastiaan R. Bloem, MD, PhD, Department of Neurology, Radboud University Nijmegen Medical Center, the Netherlands, and Patrik Brundin, MD, PhD, Laboratory of Translational Parkinson's Disease Research, Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, MI, discuss how a well-done examination provides important diagnostic information. They write, "Details about how to perform certain clinical tests can be retrieved from standard neurological textbooks, but many useful clinical tips and tricks have been simply transmitted from teacher to student...such clinical pearls were never laid down in accessible form for a broad readership.
"We hope this new section offers readers a glimpse into the examination room of experienced clinicians who share their clinical pearls," say Dr. Bloem and Dr. Brundin.

Adapted by MNT from original media release

Cynapsus reports positive top-line results from CTH-105 phase II trial of APL-130277 to treat Parkinson's Disease

Published 20 November 2014

Cynapsus Therapeutics, a specialty pharmaceutical company focused on Parkinson’s disease, announced positive top-line results from its CTH-105 Phase II clinical trial of APL-130277 for the management of OFF motor symptoms of Parkinson’s disease.
APL-130277 is the Company's fast-acting, sublingual, thin filmstrip formulation of apomorphine. OFF episodes are a complication of Parkinson's disease that leave patients rigid and unable to move and communicate.
An estimated one quarter to one half of all people with Parkinson's disease whose symptoms are otherwise managed with ongoing drug therapy, experience OFF episodes at least once daily and up to six times daily, with each episode lasting between 30 and 120 minutes.
"The purpose of the CTH-105 study was to better understand the APL-130277 dose range that produced efficacy as measured by the change in the Unified Parkinson's Disease Rating Scale (UPDRS) part III, a scale used by neurologists to measure the severity of Parkinson's disease OFF and motor symptoms, compared with baseline. We are encouraged that APL-130277 provided clinical benefit at all five doses used in this study," said Dr. Albert Agro, Chief Medical Officer of Cynapsus.
"These preliminary data show that APL-130277 was able to convert patients from a severe OFF state in the morning to ON. In addition, treatment was associated with a 45% improvement in motor function based on the change in UPDRS part III from baseline. The mean dose needed to terminate the OFF episode was 18.4mg. In addition, those patients achieving a response at higher doses appeared to adapt to the treatment, as seen by the lack of nausea at higher doses."
In the CTH-105 multicenter open-label study, APL-130277 was assessed in 16 patients with Parkinson's disease who experience the debilitating effects of OFF episodes, with a total duration of OFF of at least two hours daily.
To date, 16 patients have completed the dosing regimen, which was the planned sample size for the study. Due to over enrollment, an additional three patients are still in dosing. OFF episodes were achieved by having patients take their last dose of levodopa the night before they came into the clinic.
Patients were not allowed to take their first dose of levodopa in the morning, resulting in a severe OFF state that is one of the most difficult to convert and maintain in an ON state.
Patients were then given escalating doses of APL-130277 (at a minimum of three hours between doses) until ON was achieved, as documented by study staff, the patient, and a clinician assessment of UPDRS part III. The UPDRS III part score was measured at 15, 30, 45, 60 and 90 minutes.
All five doses of APL-130277 used in the study (10, 15, 20, 25 and 30mg) resulted in patients moving from OFF to ON. The mean baseline UPDRS part III in an OFF state was 41.4, and the maximum mean change from baseline UPDRS part III was 18.4.
The mean dose required to convert patients to ON was 18.4mg. The onset of a clinically meaningful improvement was seen in as early as 10 minutes and lasted up to 90 minutes, the last time point measured in this study.
The mean time to ON as reported by study staff was 22 minutes. Cynapsus believes that these data strongly support the conclusion that APL-130277 is associated with the robust and rapid management of OFF episodes.
The graph below (click the multimedia link) shows the mean change from baseline in UPDRS part III for the 14 subjects who converted to ON. Two patients dosed at the highest available dose (30mg) did not achieve a full ON as assessed by the investigator, suggesting that higher doses may be required for some patients.
Treatment with APL-130277 was safe and well tolerated. Nausea was reported by three subjects at doses of 10, 15 and 20mg. One of these patients also experienced a mild episode of emesis. There were no reports of nausea at higher doses. There were no reports of local irritation or hypotension in any subject treated. A total of 60 doses of APL-130277 were administered to the 16 patients who completed dosing in the CTH-105 study.
Based on the findings of this study, Cynapsus is planning to conduct pivotal studies of longer duration and with larger patient numbers to confirm these results. These pivotal studies are expected to form the registration package necessary for a 505(b)(2) New Drug Application with the U.S. Food and Drug Administration expected to be submitted in 2016.
"The results of this Phase 2 trial are important as the data show that APL-130277 provided Parkinson's patients with a rapid improvement in motor function during OFF episodes," said Anthony Giovinazzo, President and CEO of Cynapsus.
"APL-130277 is being developed to address a significant unmet need facing people with Parkinson's disease today. The CTH-105 trial results lead us to maintain that APL-130277 may be able to serve the majority of Parkinson's patients seeking to restore movement rapidly, on demand, with an easy to retrieve and to administer form of apomorphine, the only approved and most efficacious drug for this purpose."
"OFF episodes are debilitating events for people with Parkinson's disease. A recent survey by The Michael J. Fox Foundation of 3,000 Parkinson's patients revealed that nearly half said their OFF time was moderate or severe, causing them to avoid or stop activities," said Dr. Todd Sherer, CEO of The Michael J. Fox Foundation for Parkinson's Research, which provided $500,000 in funding for this study.
"A rapid and reliable therapy that can address OFF episodes would be a major advancement in treatment. These results suggest that APL-130277 could provide patients with improved quality of life, and as supporters of this program from its early days, we look forward to continued success in Phase 3 trials."
th.einnews.com/article/235693406/oa1KT4UfRQ3tBYms?n=2&code=ga_qGBxHZ2aVYO4P

Housework, Commute Linked to Parkinson's Disease





People who are active are less likely to develop Parkinson's disease, according to a new study.
After following 43,368 people in Sweden for an average of 12.6 years, researchers found that even "a medium amount" of physical activity significantly lowers the risk of the neurodegenerative disorder.
The latest involved data from 27,863 females and 15,505 males participating in the Swedish National March Cohort. None of the participants had Parkinson's disease at the start of the study. Participants were followed from Oct. 2007 to Dec. 2010.
Researchers identified 286 participants who developed Parkinson's disease. 
Further analysis revealed that people who spent more than six hours a week on household and community activity were 43 percent less likely to develop Parkinson's disease compared to those who spent less than two hours per week on the same types of activities. The study also revealed that men with "a medium level" of total physical activity were 45 percent less likely to develop Parkinson's disease. The study defined moderate physical activity as performing an average of 39.1 metabolic equivalent hours per day. Metabolic equivalent is determined by quantifying the estimated oxygen consumption associated with physical activity.
"Our study has a number of strengths. This was a prospective study including both males and females, and all information on physical activity was assessed before the disease occurrence, making recall bias and reverse causation less likely," study author Karin Wirdefeldt, researcher at the Department of Medical Epidemiology and Biostatistics and Department of Clinical Neuroscience, said in a news release.
"Another major strength of this study is that we considered the entire spectrum of daily energy output, rather than purely focusing on dedicated exercising. Further, we conducted a rich set of sensitivity analyses to test the robustness of our findings," she noted.
"We found that a medium level of daily total physical activity is associated with a lower risk of Parkinson's disease. The protective effect of physical activity was further supported when we summarized all available evidence from published prospective cohort studies. These findings are important for both the general population and for the healthcare of patients with Parkinson's disease," Wirdefeldt concluded.
The latest study was published online in Brain: A Journal of Neurology.